drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Intravenous anti‑EGFR/c‑MET bispecific monoclonal antibody that blocks ligand‑driven EGFR and MET receptor signaling and can engage Fc‑mediated cytotoxicity (ADCC/ADCP).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific monoclonal antibody targeting EGFR and c-MET that inhibits ligand-driven receptor signaling to suppress downstream MAPK and PI3K–AKT pathways (including MET-driven bypass resistance) and leverages an intact Fc to induce ADCC/ADCP against EGFR/MET-expressing tumor cells.
drug_name
MCLA-129
nct_id_drug_ref
NCT06015568